HIV inactivation in plasma products.
This is a review of therapeutic plasma products viz., coagulation factor concentrates, immunoglobulins, volume expanders, and protease inhibitors, and the progress made in rendering them free from transmitting infectious virus. Problems associated with the development of plasma products and the risks associated with their use are addressed. The recent technical advances designed to inactivate the hepatitis virus which led to the inactivation of HIV while preserving most of the biologic activity are reviewed. Today manufactured plasma products are essentially free from transmitting viral diseases of any significant clinical consequences.
Mozen
M M
MM
Biochemical Research & Development, Miles/Cutter Biological, Berkeley, CA 94701.
D000998:Antiviral Agents; D001779:Blood Coagulation Factors / Q000302:isolation & purification; D006678:HIV / Q000254:growth & development*; D006801:Humans; D007136:Immunoglobulins / Q000302:isolation & purification; D010949:Plasma / Q000382:microbiology*; D010952:Plasma Substitutes / Q000302:isolation & purification; D011480:Protease Inhibitors / Q000302:isolation & purification; D012307:Risk Factors
D000998:Antiviral Agents; D001779:Blood Coagulation Factors; D007136:Immunoglobulins; D010952:Plasma Substitutes; D011480:Protease Inhibitors